mRNA and DNA Detection of Human Papillomaviruses in Women of All Ages Attending Two Colposcopy Clinics
Open Access
- 15 November 2012
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (11) , e49205
Abstract
HPV infection is a common finding, especially in young women while the majority of infections are cleared within a short time interval. The aim of this study was to examine the efficacy of HPV DNA and mRNA testing in a population attending colposcopy units of two University hospitals. 1173 liquid based cervical samples from two colposcopy clinics were tested for HPV DNA positivity using a commercial typing kit and HPV E6/E7 mRNA positivity with a flow cytometry based commercial kit. Statistic measures were calculated for both molecular tests and morphological cytology and colposcopy diagnosis according to histology results. HPV DNA, high-risk HPV DNA, HPV16 or 18 DNA and HPV mRNA was detected in 55.5%, 50.6%, 20.1% and 29.7% of the cervical smears respectively. Concordance between the DNA and the mRNA test was 71.6% with their differences being statistically significant. Both tests’ positivity increased significantly as lesion grade progressed and both displayed higher positivity rates in samples from women under 30 years old. mRNA testing displayed similar NPV, slightly lower sensitivity but significantly higher specificity and PPV than DNA testing, except only when DNA positivity for either HPV16 or 18 was used. Overall mRNA testing displayed higher clinical efficacy than DNA testing, either when used as a reflex test or as an ancillary test combined with morphology. Due to enhanced specificity of mRNA testing and its comparable sensitivity in ages under 25 or 30 years old, induction of mRNA testing in young women could be feasible if a randomized trial verifies these results.Keywords
This publication has 33 references indexed in Scilit:
- Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA studyThe Lancet Oncology, 2011
- Triage of Women with Low-Grade Cervical Lesions - HPV mRNA Testing versus Repeat CytologyPLOS ONE, 2011
- Nucleic Acid Sequence-Based Amplification Assay for Human Papillomavirus mRNA Detection and Typing: Evidence for DNA AmplificationJournal of Clinical Microbiology, 2010
- A Comparison of Linear Array and Hybrid Capture 2 for Detection of Carcinogenic Human Papillomavirus and Cervical Precancer in ASCUS-LSIL Triage StudyCancer Epidemiology, Biomarkers & Prevention, 2008
- Human Papillomavirus in Cervical Cancer Screening: Important Role as BiomarkerCancer Epidemiology, Biomarkers & Prevention, 2008
- HPV DNA testing in cervical cancer screening: From evidence to policiesGynecologic Oncology, 2006
- Emerging Infections: Genital Human Papillomavirus InfectionClinical Infectious Diseases, 2006
- Presence of E6 and E7 mRNA from Human Papillomavirus Types 16, 18, 31, 33, and 45 in the Majority of Cervical CarcinomasJournal of Clinical Microbiology, 2006
- High-Throughput Cervical Cancer Screening Using Intracellular Human PapillomavirusE6andE7mRNA Quantification by Flow CytometryAmerican Journal of Clinical Pathology, 2005
- Biological activities and molecular targets of the human papillomavirus E7 oncoproteinOncogene, 2001